The lancet oncology
-
The lancet oncology · Jul 2021
Multicenter StudyPralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Oncogenic alterations in RET have been identified in multiple tumour types, including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC. ⋯ Blueprint Medicines.
-
The lancet oncology · Jul 2021
Multicenter StudyColorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study.
Colorectal cancer screening programmes and uptake vary substantially across Europe. We aimed to compare changes over time in colorectal cancer incidence, mortality, and stage distribution in relation to colorectal cancer screening implementation in European countries. ⋯ German Cancer Aid (Deutsche Krebshilfe) and the German Federal Ministry of Education and Research.
-
The lancet oncology · Jul 2021
Multicenter StudyVariation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study.
Existing clinical practice guidelines for carriers of pathogenic variants of DNA mismatch repair genes (Lynch syndrome) are based on the mean age-specific cumulative risk (penetrance) of colorectal cancer for all carriers of pathogenic variants in the same gene. We aimed to estimate the variation in the penetrance of colorectal cancer between carriers of pathogenic variants in the same gene by sex and continent of residence. ⋯ National Health and Medical Research Council, Australia.